Solebury Trout partners with private and public companies across sectors, helping management teams tackle complex investor relations challenges, capitalize on corporate communications opportunities, access the market and prepare for capital raising. More than 60 professionals with expertise in investor relations, equity research, portfolio management, private equity, investment banking and corporate communications work at Solebury Trout. The company was formed through the combination of Solebury Communications with the Trout Group, the premier investor relations and strategic advisory firm serving the biotechnology industry, providing corporate access and hosting dozens of well-attended conferences and thought leader events. Solebury Trout is affiliated with leading equity capital markets advisory firm Solebury Capital, which in 2017 advised on nearly 40 percent of the IPO proceeds in the U.S., and is owned by PNC, one of the largest diversified financial institutions in the country.
https://www.soleburytrout.com/lifesciences
TroutTalks Ep8 : Dr. Eric Pierce "Treating Retinitis Pigmentosa with Human Retinal Progenitor Cells"
Dr. Pierce is an ophthalmologist and molecular geneticist whose research program is dedicated to understanding the molecular mechanisms of Inherited retinal degenerations (IRDs) and improving therapeutic interventions for these conditions. IRDs are a leading cause of blindness worldwide, and are characterized by progressive dysfunctionand death of retinal photoreceptor cells. Dr. Pierce's research program is focused on identifying new IRD disease genes, investigating the mechanism by which mutations in the identified genes lead to blindness, and using this information about disease pathogenesis to develop gene and genetic therapies to prevent vision loss.